medwireNews: The use of insulin degludec is associated with a reduced risk of recurrent nocturnal hypoglycaemia, as measured by hourly plasma glucose in adults with type 1 diabetes, the results of the overnight partial study of the HypoDeg study suggest.
The key results of the Phase 4 crossover study previously reported by medwireNews showed that participants with at least one episode of severe nocturnal hypoglycemia in the past 2 years had significantly lower rates of symptomatic nocturnal hypoglycemia when using insulin degludec Compared to glargine U100 used as basic therapy insulin.
The overnight partial study reported by Julie Brøsen (Nordsjællands Hospital, Hillerød, Denmark) at the ADA’s 81st virtual scientific sessions included 51 of the 149 HypoDeg participants who had hourly plasma glucose readings for 196 nights.
Brøsen said the proportion of nights with hypoglycemic episodes was lower during treatment with Degludec than with glargine, namely 33% and 67%, respectively.
The team then calculated the probability of experiencing a hypoglycaemia-free night at level 1 (≤70 mg / dl /) [3.9 mmol/L]) and level 2 (<54 mg / dl [3.0 mmol/L]), which found that Degludec was associated with a significantly 54% lower risk for level 1 and a significantly 64% lower risk for level 2 hypoglycemia compared to glargine U100.
medwireNews is an independent medical news service from Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group
Scientific meetings of the ADA; 25-29 June 2021
